A recent study reveals that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Published data in a leading medical journal demonstrates that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying such medications should be cognizant of the danger of rapid weight regain when the medication ends," warns lead investigator Dr. Susan Jebb.
This pace of regain means a return to original mass in about a year and a half.
Comparing Therapies
The research, which reviewed dozens of trials involving thousands of patients, compared the effects of these new drugs with older methods.
The team point out that people who lose weight through lifestyle changes alone generally see a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
Understanding the Fast Regain
Experts propose the mechanism of the jabs explains the amplified rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which controls hunger.
"Artificially providing the hormone concentrations several times higher than the body's typical production might result in the system to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making binge eating far more likely."
A Lifelong Issue?
The NHS advise the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, given the likelihood of weight regain, the therapy might need to be life-long.
This opinion is reinforced by drug manufacturers, who state that the findings "emphasize the chronic nature of excess weight," comparing it to managing conditions like diabetes.
Patient Accounts
People who have come off the jabs report a sudden return of cravings.
"It was like a trigger activating and you're instantly extremely hungry," described a patient.
This difficulty is compounded if patients have not adopted sustainable lifestyle or habit changes during treatment.
Growing Adoption
Figures show that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is more common among females than men.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, clinicians caution that while these medications are potent tools for weight loss, they are not a permanent solution and long-term success likely depends on ongoing behavioural management.
